LOG IN
SIGN UP
MARKET
ESPR
ESPR
Esperion Therape
NASDAQ
Real-time Quotes | Nasdaq Last Sale
5.80
+0.29
+5.26%
After Hours: 5.86 +0.06 +1.03% 19:57 05/27 EDT
OPEN
5.51
PREV CLOSE
5.51
HIGH
5.85
LOW
5.38
VOLUME
563.31K
TURNOVER
0
52 WEEK HIGH
26.77
52 WEEK LOW
3.280
MARKET CAP
365.44M
P/E (TTM)
-0.8307
1D
5D
1M
3M
1Y
5Y
Esperion (ESPR) Up More Than 12% YTD: What's Driving the Rally?
Esperion's (ESPR) marketed drugs are the key drivers of the stock. Sales of the drugs increase more than 100% during the first quarter. Strong sales growth is expected to continue in 2022 as well as 2023.
Zacks · 2d ago
Esperion to Participate in Upcoming H.C. Wainwright Global Investment Conference
ANN ARBOR, Mich., May 17, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that President and Chief Executive Officer, Sheldon Koenig, will participate in a fireside chat at the upcoming H.C. Wainwright Global Investment Conference on Tues...
GlobeNewswire · 05/17 12:00
Esperion Therapeutics, Inc. (NASDAQ:ESPR): Are Analysts Optimistic?
Esperion Therapeutics, Inc. ( NASDAQ:ESPR ) is possibly approaching a major achievement in its business, so we would...
Simply Wall St. · 05/13 14:28
Esperion Therapeutics's Return On Capital Employed Insights
According to Benzinga Pro data, during Q1, Esperion Therapeutics (NASDAQ:ESPR) posted sales of $18.84 million. Earnings were up 12.88%, but Esperion Therapeutics still reported an overall loss of $56.73 million.
Benzinga · 05/13 13:54
--JPMorgan Upgrades Esperion Therapeutics to Neutral From Underweight; Price Target is $6
MT Newswires · 05/05 06:00
Esperion (ESPR) Q1 Earnings Beat on Robust Demand for Drugs
Esperion Therapeutics (ESPR) reports solid first-quarter results, beating estimates for earnings and sales. Cost-savings programs boost margins. Stock rallies.
Zacks · 05/04 14:52
Esperion stock rises as Q1 revenue soars 136% Y/Y
Esperion (NASDAQ:ESPR) stock rose May 3 after Q1 results beat analysts' estimates. Q1 total revenues increased +136% Y/Y to ~$18.84M Y/Y. U.S. net product revenue of cholesterol lowering therapies Nexletol (bempedoic
Seekingalpha · 05/03 16:04
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Benzinga · 05/03 13:01
No Data
Learn about the latest financial forecast of ESPR. Analyze the recent business situations of Esperion Therape through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating
Based on 11 analysts
Hold
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
9.09%Strong Buy
36.36%Buy
36.36%Hold
18.18%Under-perform
0.00%Sell
Analyst Price Target
The average ESPR stock price target is 10.85 with a high estimate of 22.00 and a low estimate of 3.500.
Current 5.80
EPS
Actual
Estimate
-2.24-1.68-1.12-0.56
Institutional Holdings
Institutions: 229
Institutional Holdings: 60.88M
% Owned: 96.63%
Shares Outstanding: 63.01M
TypeInstitutionsShares
Increased
44
12.17M
New
45
19.46M
Decreased
26
780.95K
Sold Out
48
1.90M
- Performance
- Asset Allocation
- Dividend History
No Data
Industry
Pharmaceuticals
+0.69%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
President/Chief Executive Officer/Director
Sheldon Koenig
General Counsel
Benjamin Looker
Other
JoAnne Foody
Other
Eric Warren
Lead Director/Independent Director
Nicole Vitullo
Director
Jeffrey Berkowitz
Independent Director
Seth Fischer
Independent Director
Alan Fuhrman
Independent Director
Antonio Gotto
Independent Director
Stephen Rocamboli
Independent Director
Jay Shepard
Independent Director
Tracy Woody
No Data
No Data
About ESPR
Esperion Therapeutics, Inc. is a lipid management company. The Company is a pharmaceutical company focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). Its bempedoic acid and the bempedoic acid / ezetimibe combination tablets are oral, once-daily, non-statin, LDL-C lowering medicines for patients with atherosclerotic cardiovascular disease (ASCVD), or heterozygous familial hypercholesterolemia (HeFH). Its products include NEXLETOL, NILEMDO, NEXLIZET and NUSTENDI. NEXLETOL and NILEMDO are ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors. NEXLIZET and NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine.
Webull offers kinds of Esperion Therapeutics Inc stock information, including NASDAQ:ESPR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ESPR stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading ESPR stock methods without spending real money on the virtual paper trading platform.